IL1B and nonpapillary renal cell carcinoma: The SPARC-1 trial (NCT04028245) is a phase 2 trial investigating the use of two doses of neoadjuvant spartalizumab (anti-PD-1) and canakinumab (IL-1β mAb) in patients with localized ccRCC (cT1b-T4Nany or cTanyN1) [139].